Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?

Release Date: November 30, 2018
Expiration Date: November 30, 2019
Media: Internet - based
 

Activity Overview

This Medical Crossfire® CME activity, chaired by world-renowned expert Jeffrey S. Weber, MD, PhD, will provide you with the tools needed to deliver optimal care for your patients with melanoma across multiple lines of care.

The management of melanoma has radically changed in recent years in the advanced- and adjuvant-disease settings, with new treatment options on the horizon for adjuvant treatment for high-risk stage III melanoma and neoadjuvant immunotherapy checkpoint blockade showing promise in early clinical findings.

Benefits of Participating

  • Learn the benefits of checkpoint inhibition in treating patients with melanoma
  • Hear about challenging case discussions in the treatment of patients with melanoma
  • Understand how to apply the results of recent clinical trials to your practice
  • Learn how to manage immune-related adverse events in patients with melanoma
  • Explore future directions for immune checkpoint inhibition in patients with melanoma

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with melanoma. Dermatologists, dermatopathologists pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of melanoma are also invited to participate.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  1. Detail approaches to identify patients for immunotherapy and stratify risk in the adjuvant-treatment setting of melanoma
  2. Review clinical data with immune checkpoint inhibition in multiple treatment settings in melanoma
  3. Evaluate the latest clinical trial evidence on the use of combination regimens in patients with melanoma
  4. Examine strategies that allow for identification and effective treatment of immune-related toxicities in patients with melanoma

Faculty, Staff, and Planners' Disclosure

Moderator

Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY

Disclosures: Consultant: BMS, GSK, Merck, Genentech, AstraZeneca, Incyte, Celldex, Novartis, Takeda, Pfizer, Alter, CytoMx; Stock/Shareholder: Altor, Biond, CytoMx; Other support: Named on a PD-1 biomarker patent by Biodesix

Faculty

Tara C. Mitchell, MD
Medical Oncologist
Assistant Professor of Medicine
Hematology-Oncology Division
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, PA

Disclosures: Grant/Research Support: Merck, BMS, Incyte; Consultant: Merck, BMS, Incyte, Aduro

Anna C. Pavlick, BSM, MS, DO, MBA
Professor, Department of Medicine
Professor, Ronald O. Perelman Department of Dermatology
Assistant Director, Clinical Research Education
Co-Director, Melanoma Program
NYU Medical Oncology Associates
New York, NY

Disclosures: Grant/Research Support: Merck, Regeneron, BMS, Celldex, Iovance; Consultant: Regeneron, Sanofi/Genzyme, Merck, BMS, Novartis

Michael A. Postow, MD
Melanoma and Immunotherapeutics Service
Memorial Sloan Kettering Cancer Center
New York, NY
 
 

Disclosures: Grant/Research Support: BMS, RGenix, Infinity, Novartis, Merck, Array Biopharma; Consultant: BMS, Novartis, Merck, Array Biopharma, Newlink Genetics, Incyte, Aduro; Other Support: Honoraria from BMS, Merck

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
 
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By